trending Market Intelligence /marketintelligence/en/news-insights/trending/xbebzk6sk8dwprvcl-pxcq2 content esgSubNav
In This List

Regulus terminates chief medical officer as part of restructuring

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy


Regulus terminates chief medical officer as part of restructuring

Regulus Therapeutics Inc. said Mark Deeg will be terminated as its chief medical officer as part of the restructuring process to preserve capital.

The San Diego-based biopharmaceutical company has paused its recruitment activities for RG-012, its potential treatment for Alport syndrome, and a phase 1 trial of RGLS4326, another kidney disease drug.

Regulus is reducing its workforce by about 60% and expects to complete the reduction in the third quarter. It expects the restructuring to yield over $20 million in annualized savings, extending its cash runway into mid-2019.